Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Exclusion Criteria

• •Any other investigational agents within 28 days of the anticipated C1D1 of 225Ac-PSMA-R2 therapy
• •Any systemic anti-cancer therapy within 28 days of the anticipated C1D1 of 225Ac-PSMA-R2 therapy
• •Uncontrolled pain or incompatibility that may result in participant's lack of ability to comply with imaging procedures
• •History of CNS metastases and symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression
• •History of myocardial infarction, angina pectoris, or coronary artery bypass graft within 6 months prior to ICF signature and/or clinically active significant cardiac disease
• •Diagnosis of other malignancies in the past three years expected to alter life expectancy or may interfere with disease assessment